Efficacy of fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications: subgroup analysis of the randomised, placebo-controlled FOCUS study

被引：0
|
作者：
Silberstein, Stephen [1 ]
Cohen, Joshua M. [2 ]
Ramirez-Campos, Verena [2 ]
Yang, Ronghua [2 ]
Galic, Maja [3 ]
Ning, Xiaoping [2 ]
Jann, Adelene [4 ]
机构：
[1] Jefferson Headache Ctr, Philadelphia, PA USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] NYU Langone Hlth, New York, NY USA
来源：
CEPHALALGIA | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC-PO-156
引用
收藏
页码：226 / 227
页数：2
相关论文
共 50 条
  • [1] Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-Controlled FOCUS Study
    Silberstein, Stephen
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    ANNALS OF NEUROLOGY, 2020, 88 : S157 - S158
  • [2] Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study
    Silberstein, Stephen
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Galic, Maja
    Ning, Xiaoping
    Jann, Adelene
    NEUROLOGY, 2020, 94 (15)
  • [3] Clinically meaningful responses to fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the randomised, placebo-controlled FOCUS study
    Ashina, Sait
    Ramirez-Campos, Verena
    Cohen, Joshua M.
    Janka, Lindsay
    Spierings, Egilius L.
    CEPHALALGIA, 2019, 39 : 227 - 227
  • [4] Clinically Meaningful Responses to Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2-4 Migraine Preventive Medications in the Randomized, Placebo-controlled FOCUS Study
    Ashina, Sait
    Ramirez-Campos, Verena
    Cohen, Joshua
    Janka, Lindsay
    Spierings, Egilius L. H.
    NEUROLOGY, 2020, 94 (15)
  • [5] Impact of fremanezumab on any acute headache medication use in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study
    Newman, Lawrence
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Janka, Lindsay
    Diener, Hans-Christoph
    CEPHALALGIA, 2019, 39 : 238 - 238
  • [6] Efficacy of fremanezumab by country in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled focus study
    Spierings, E. L. H.
    Ning, X.
    Cohen, J. M.
    Ramirez-Campos, V.
    Yang, R.
    Reuter, U.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [7] Efficacy of fremanezumab in male patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the randomised, placebo-controlled FOCUS study
    MaassenVanDenBrink, Antoinette
    Terwindt, Gisela
    Cohen, Joshua M.
    Yang, Ronghua
    Ramirez-Campos, Verena
    Galic, Maja
    Ning, Xiaoping
    Karppa, Mikko
    CEPHALALGIA, 2019, 39 : 251 - 251
  • [8] Safety and tolerability of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Ferrari, M. D.
    Cohen, J. M.
    Ning, X.
    Galic, M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 625 - 625
  • [9] Safety and tolerability of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Ferrari, Michel D.
    Cohen, Joshua M.
    Ning, Xiaoping
    Galic, Maja
    Yang, Ronghua
    CEPHALALGIA, 2019, 39 : 251 - 252
  • [10] Efficacy with fremanezumab in migraine patients with comorbid moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS study
    Lipton, Richard B.
    Cohen, Joshua M.
    Ramirez-Campos, Verena
    Yang, Ronghua
    Ning, Xiaoping
    Galic, Maja
    Buse, Dawn C.
    CEPHALALGIA, 2019, 39 : 210 - 211
12345